Long-term RNA Interference Gene Therapy in a Dominant Retinitis Pigmentosa Mouse Model

Li Jiang,Houbin Zhang,Alexander M. Dizhoor,Shannon E. Boye,William W. Hauswirth,Jeanne M. Frederick,Wolfgang Baehr

DOI: https://doi.org/10.1073/pnas.1112758108

IF: 11.1

2011-01-01

Proceedings of the National Academy of Sciences

Abstract:RNA interference (RNAi) gene silencing is a potential therapeutic strategy for dominant retinal degeneration disorders. We used self-complementary (sc) AAV2/8 vector to develop an RNAi-based gene therapy in a dominant retinal degeneration mouse model expressing bovine GCAP1(Y99C). We established an in vitro shRNA screening assay based on EGFP-tagged bovine GCAP1, and identified a shRNA that effectively silenced the bovine GCAP1 transgene with ∼80% efficiency. Subretinal injection of scAAV2/8 carrying shRNA expression cassette showed robust expression as early as 1 wk after injection. The gene silencing significantly improved photoreceptor survival, delayed disease onset, and increased visual function. Our results provide a promising strategy toward effective RNAi-based gene therapy by scAAV2/8 delivery for dominant retinal diseases.